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Abstract Hydrogel nanoparticles of cross-linked polyvinylpyr-
rolidone (PVP-NP) (35^50 nm in diameter) containing fluor-
esceinated dextran (FITC-Dx) were encapsulated in
reconstituted Sendai viral envelopes containing only the fusion
(F) protein (F-virosomes1). Incubation of these loaded F-viro-
somes with human hepatoblastoma cells (HepG2) in culture
resulted in membrane-fusion-mediated delivery of NPs to the cell
cytoplasm, as inferred from the ability of cells to internalize
FITC-Dx loaded PVP-NP (PVPf-NP) in the presence of azide
(an inhibitor of the endocytotic process). Introduction of PVPf-
NP into the HepG2 cells was assured by selective accumulation
of FITC fluorescence in the cytosolic compartment. The
structural integrity of the internalized PVPf-NP was also
confirmed by fluorescence microscopy and ultracentrifugation
analysis. The potential usefulness of PVP-NP-mediated cytosolic
release of water soluble drugs both in vitro and in vivo has been
established for the first time. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Despite improvements in viral and non-viral vector systems,
a major hurdle in the delivery of drugs and other macromo-
lecules into the desired cell types is crossing the permeability
barrier imposed by the plasma membrane followed by the
controlled release inside the cytoplasm [1]. On the other
hand, it is known that controlled release of drugs can be
signi¢cantly improved by using nanoparticulate carriers [1].
Among such carriers, ultralow-sized hydrogel nanoparticles
[2] made up of polyvinylpyrrolidone (PVP-NP) have been se-
lected as the polymer component and are highly biocompat-
ible [3]. Besides signi¢cant progress made in the ¢eld of bio-
medical applications of nanotechnology, di¡erent factors
(size, surface, cell-speci¢c uptake of NPs and endosomal es-
cape) associated with NP targeting of drugs could be pivotal
for a successful outcome [4]. While size, surface and cell-spe-
ci¢c uptake of NPs have been resolved to some extent [1],
existing technology fails to deliver drug-loaded NPs directly
inside the cytosol of desired cell types evading endosomal
pathway for its expected optimum action [4]. In the past
few years, engineered Sendai viral envelopes (F-virosomes)
are known to speci¢cally bind and fuse e⁄ciently with the
plasma membrane of hepatocytes both in vitro and in vivo
and served as excellent carriers for fusion-mediated microin-
jection of various biologically active molecules into their cy-
tosolic compartments [5^10].
In the present study, PVP-NP of de¢ned size (approxi-
mately 50 nm in diameter) loaded with £uorescein isothiocya-
nate dextran (FITC-Dx; model drug of choice) have been
entrapped within F-virosomes. We demonstrate that these
loaded F-virosomes (delivery vehicle inside a delivery vehicle)
fuse with HepG2 cell membranes and microinject the encap-
sulated FITC-Dx-loaded polyvinylpyrrolidone NP (PVPf -NP)
into the cell cytoplasm. The delivery of PVPf -NPs from viro-
somes to the cytosol of the target cells is reported for the ¢rst
time in a systematic and quantitative fashion. The e⁄cacy of
this unique hybrid delivery system with respect to controlled
release of drugs inside the cytosolic compartment is discussed.
2. Materials and methods
2.1. Preparation of PVPf -NP
PVPf -NP were made following our previous communication [11]. In
brief, 40 ml of 0.03 M sodium bis-2-ethylhexylsulfosuccinate (AOT)
solution in hexane was taken and to it 280 Wl of freshly distilled vinyl
pyrrolidone, 50 Wl of N,NP-methylene bisacrylamide (0.049 g/ml), 20 Wl
N,N,NP,NP-tetramethylethylenediamine and 20 Wl of ammonium per-
sulfate (saturated solution) and 50 Wl (160 mg/ml in water) of FITC-
Dx (Sigma, St. Louis, MO, USA; mol. wt. 19.3 kDa) were added.
Polymerization was carried out at 37‡C for 8 h with continuous stir-
ring. After the completion of the reaction the excess solvent (hexane)
was evaporated in a rotatory evaporator and the dry mass was resus-
pended in 10 ml of water by sonication. Then, 1 ml of 30% CaCl2
solution was added dropwise with continuous stirring to precipitate
the AOT as calcium salt of bis (2-ethyl-hexyl) sulfosuccinate
(Ca(DEHSS)2) followed by dialysis against water. Ca(DEHSS)2 was
separated by centrifugation. After separating the unentrapped FITC-
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Dx by gel ¢ltration, the supernatant containing PVPf -NP was lyophi-
lized to dry powder for subsequent use. The amount of FITC-Dx
entrapped inside PVP-NP was calculated (200 Wg of FITC-Dx/mg of
PVPf -NP) and their average diameter was determined by electron
microscopy [2].
2.2. Preparation of PVPf -NP loaded F-virosomes
Reconstituted Sendai viral envelopes containing F-protein (F-viro-
some) were prepared as described earlier [5]. The Triton X-100 (TX-
100)-solubilized fraction of virus was mixed with PVPf -NP (500 Wg of
PVPf -NP/mg of viral protein) and reconstituted by stepwise removal
of detergent using SM2 biobeads. The unentrapped PVPf -NP ad-
sorbed on the surface of virosomal membrane was removed by re-
peated washing with cold 0.01 M Tris-bu¡ered saline (TBS), pH 7.4.
Furthermore, to remove the residual amount of aggregated form of
PVPf -NP and FITC-Dx adsorbed on the virosomal surface, the
loaded virosomes were subjected to sucrose density gradient ultracen-
trifugation following the protocol of Paternoster et al. [12]. The
amount of entrapped PVPf -NP was determined by £uorescence mea-
surement at 490/520 nm (excitation/emission). FITC-Dx-loaded F-vi-
rosomes were made following our published procedure for entrapping
water soluble molecules [5,7]. Each preparation of such loaded viro-
somes was tested for both structure and function following our pub-
lished protocol [6].
2.3. Cells
HepG2 (human hepatoblastoma cells), NIH3T3 (mouse ¢broblast)
and CHO (Chinese hamster ovary) cells were maintained in Dulbec-
co’s modi¢ed Eagle’s medium (DMEM) containing 10% fetal calf
serum (FCS), sodium pyruvate (110 Wg/ml), penicillin (100 U/ml)
and streptomycin (100 Wg/ml) under 5% CO2. All cell culture reagents
were procured from Invitrogen, USA.
2.4. Fusion-mediated delivery of PVPf -NP and FITC-Dx into
HepG2 cells
2.4.1. Spectro£uorimetric measurements. Single cell suspensions of
HepG2 cells were made by lifting the cells from monolayer with ethyl-
enediaminetetraacetate (EDTA) [7]. The cells were ¢nally suspended
in DMEM without serum to obtain 1.0U106 cells/ml. Loaded F-vi-
rosomes were incubated with cells with varying doses and time at
37‡C. The virosome^cell mixtures were washed with cold Dulbecco’s
phosphate-bu¡ered saline (DPBS) containing 2 mM Ca2 and 2 mM
Mg2 thrice and ¢nally incubated at 4‡C for 10 min in DPBS con-
taining 5 mM EDTA to remove (EDTA-stripping) the cell surface-
bound (unfused) virosomes as standardized earlier [7]. The cell pellets
after EDTA-stripping were solubilized in TBS containing 0.3% TX-
100 and £uorescence was measured with a spectro£uorometer (model
RF 540, Shimadzu Corp., Kyoto, Japan) at 490/520 nm (excitation/
emission) wavelength. Heat-treated F-virosomes (incubated at 56‡C
for 20 min), F-virosomes incubated with NIH3T3 and CHO cells
and F-virosomes pre-incubated with mouse anti-F glycoprotein anti-
body raised in our laboratory [13] were taken as appropriate controls.
Fluorescence value of virosome^cell complex without EDTA-stripping
was used to calculate the percentage of internalization of PVPf -NP
and/or FITC-Dx by liver cells. Sodium azide is known to be an e⁄-
cient inhibitor of endocytosis process [14]. Binding and fusion of
virosomes and heat-treated virosomes with target cells were studied
in the presence of 10 mM azide as described earlier [6,7].
2.4.2. Fluorescence microscopy. Glass coverslips (Erie Scienti¢c,
Portsmouth, NH, USA) were coated with polylysine (PL; Sigma,
USA) following standard protocol [15]. HepG2 cells were grown in
24-well plates (Becton Dickinson, Cockeysville, MD, USA) on PL-
coated coverslips and were incubated with either PVPf -NP or FITC-
Dx-loaded F-virosomes in DMEM without serum. HepG2 cells mixed
with heat-treated loaded F-virosomes were used as controls. The me-
dium was replaced after 2 h with DMEM containing 10% FCS and 10
mM sodium azide and was incubated inside a CO2 incubator for
di¡erent times. At each time point coverslips were subjected to
EDTA-stripping and were mounted on glass slides with 10 Wl of
DMEM. Fluorescence was detected and images were recorded on
Kodak color ¢lm using an Eclipse TE 300 (Nikon, Japan) microscope.
The light source was a 100 W Hg lamp with appropriate levels of heat
and neutral density ¢lters. The £uorescein ¢lters were a standard
Nikon set, consisting of 490-nm excitation ¢lter and a 520-nm emis-
sion ¢lter. The camera system was from Nikon, Japan.
2.5. Cell fractionation
F-virosomes (PVPf -NP or FITC-Dx loaded, untreated or heat-
treated in each case) were incubated with HepG2 cells in DMEM
without serum at 37‡C for 2 h. After EDTA-stripping the cells were
washed thrice with TBS and were subjected to subcellular fractiona-
tion following our published procedure [7]. In brief, the cells were
resuspended in the isotonic homogenizing bu¡er (0.01 M Tris^HCl,
pH 7.4, containing 0.25 M sucrose) and then dispersed in a Potter^
Elvehjem type homogenizer at 4‡C. Fluorescence associated with each
fraction was analyzed and expressed as percent of total amount of
£uorescence associated with the whole cells. PVPf -NPs are known to
be pelleted at 100 000Ug for 4 h at 4‡C without a¡ecting their struc-
tural integrity (unpublished observation). Therefore, cytosolic frac-
tions obtained from subcellular fractionation of HepG2 cells were
further centrifuged at 100 000Ug for 4 h at 4‡C with a view to sep-
arate the intact PVPf -NP from its degraded counterpart.
3. Results
3.1. Characterization of PVPf -NP loaded F-virosomes
The purity of F-virosome preparations was checked by so-
dium dodecyl sulfate^polyacrylamide gel electrophoresis in
the presence of L-mercaptoethanol [6] and was found to be
free from any contamination by other proteins. Membrane-
fusion activity of these loaded virosomes was ascertained by
their ability to hemolyze mouse red blood cells (RBCs) in the
presence of wheat germ agglutinin [6]. The entrapped PVPf -
NP was retained in intact form inside F-virosomes in the
presence of 10% FCS over a period of 48 h in contrast to
our earlier observations indicating the ability of serum pro-
teases in degrading free PVPf -NP [2]. 5^15 Wg of PVPf -NP
was encapsulated in 1 mg of F-virosomes whereas 40^60 Wg of
free FITC-Dx was entrapped per mg of F-virosomes. Electron
microscopy of PVPf -NP (data not shown) preparations and
negatively stained loaded virosomal suspension [16] revealed
their spherical shape with size varying between 35^50 nm and
100^200 nm in diameter respectively.
3.2. Internalization of PVPf -NP into HepG2 cells delivered
through F-virosomes
Our laboratory has pioneered the observation that F-viro-
somes can bind and fuse e⁄ciently with HepG2 cells through
the interaction of terminal galactose of fusion with the asia-
Fig. 1. Dose-dependent internalization of PVPf -NP into HepG2 cells
delivered through F-virosomes. Di¡erent amounts (in terms of
F protein) of loaded F-virosomes, heat-treated F-virosomes or F-vi-
rosomes pre-incubated with anti-F antibody were incubated with
HepG2 cells in DMEM at 37‡C for 2 h. PVPf -NP-associated
£uorescein with cells was determined after EDTA-stripping as de-
scribed on Section 2.4. Black bars, F-virosomes with HepG2 cells;
hatched bars, heat-treated F-virosomes with HepG2 cells; dotted
bars, F-virosomes pre-incubated with anti-F antibody. Each value is
mean of three independent determinations.
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loglycoprotein receptors (ASGP-Rs) [5,7]. We have utilized
this system to explore the possibility of delivering PVPf -NP
of de¢ned size to the cytosolic compartment of HepG2 cells.
Uptake of PVPf -NP by cells at 37‡C was examined as a func-
tion of dose of F-virosomes. Fig. 1 shows a saturation type
curve representing cell-associated PVPf -NP. No increase of
PVPf -NP delivery was noticed beyond 100 Wg of F-virosomes
and this was employed in all subsequent experiments. Figs. 2
and 3 demonstrate that the initial rate of delivery of PVPf -NP
to HepG2 cells through F-virosomes was twice that of FITC-
Dx in the presence of 10 mM sodium azide.
The subtle molecular mechanism associated with higher rate
of internalization of NP is yet to be understood. Correspond-
ing heat-treated loaded virosomes in the presence of 10 mM
azide revealed no internalization of entrapped PVPf -NP and
FITC-Dx. On the other hand, the heat-treated loaded viro-
somes were able to bind to HepG2 cells to the same extent as
that of untreated virosomes at 4‡C (data not shown). Slight
internalization (ca. 10%) of both PVPf -NP and FITC-Dx ob-
served in the case of heat-treated F-virosomes and virosomes
pre-incubated with anti-F antibody may be due to the endo-
cytosis of bound non-fusogenic virosomes. Negligible fusion
activity (6 2%) was obtained with NIH3T3 and CHO cells as
target. Taken together, these results strongly support target-
speci¢c, membrane-fusion-mediated cytosolic delivery of
PVPf -NP by F-virosomes to the HepG2 cells.
3.3. Subcellular distribution patterns of PVPf -NP delivered by
F-virosomes and heat-treated F-virosomes: cytosolic
delivery of PVPf -NP
Table 1 shows that about 61% of the total cell-associated
£uorescence was recovered from cytosolic fraction using F-vi-
rosome as carrier. By contrast, 50% of the £uorescence was
recovered in lysosomal/mitochondrial fraction with a concom-
itant decrease (66%) in the cytosolic £uorescence in the case of
heat-treated F-virosomes. These results clearly support the
fusion-mediated delivery of PVPf -NP by F-virosomes to
HepG2 cells. Heat-treated F-virosomes being non-fusogenic
[5^7] are likely to be taken up by endocytosis leading to their
accumulation and subsequent degradation in lysosomes. Ad-
ditionally, the integrity of the PVPf -NP inside the cytosol was
assessed directly by pelleting the NPs at higher g force fol-
Fig. 2. Kinetics of accumulation of PVPf -NP into HepG2 cells de-
livered through F-virosomes. Loaded F-virosomes (100 Wg) were in-
cubated with 1.0U106 HepG2 cells at 37‡C for di¡erent times in
DMEM. The virosome^cell complexes were kept at 4‡C for 10 min
in DPBS containing 5 mM EDTA to remove surface bound F-viro-
somes (unfused). After washing, the cell pellets were solubilized in
TBS containing 0.3% TX-100 and £uorescence were measured with
a spectro£uorometer. Fluorescence unit without EDTA-stripping
was considered as 100%. 8, F-virosomes with HepG2 cells in the
presence of azide; F, heat-treated F-virosomes incubated with
HepG2 cells without azide; R, heat-treated F-virosomes with
HepG2 cells in the presence of azide; b, F-virosomes with NIH3T3
cells; a, F-virosomes pre-incubated with anti-F antibody; E, F-viro-
somes with CHO cells. The values are means of triplicate observa-
tions.
Fig. 3. Kinetics of accumulation of FITC-Dx into HepG2 cells
transferred through F-virosomes. Loaded F-virosomes (100 Wg) were
incubated with 1.0U106 HepG2 cells at 37‡C for di¡erent times in
DMEM. For details about the incubation of virosomes and £uores-
cence measurements, see the legend to Fig. 2. 8, F-virosomes with
HepG2 cells in the presence of azide; F, heat-treated F-virosomes
incubated with HepG2 cells without azide; R, heat-treated F-viro-
somes with HepG2 cells in the presence of azide; b, F-virosomes
with NIH3T3 cells; a, F-virosomes pre-incubated with anti-F anti-
body; E, F-virosomes with CHO cells. The values are means of
triplicate recordings.
Table 1
Subcellular Localization of PVPf -NP inside HepG2 cells
Virosomes Lysosomal/mitochondrial (%) Cytosol (%)
Experimental 27 61
Heat-treated 50 21
HepG2 (2.0U106) cells were incubated with loaded F-virosomes or
heat-treated F-virosomes (200 Wg F protein) in DMEM at 37‡C for
2 h. The cells were EDTA-stripped and cell fractionation was car-
ried out as described in Section 2. Fluorescence unit without
EDTA-stripping was considered as 100%. Each value is the mean of
three independent experiments.
Table 2
Integrity of PVPf -NP in the cytosolic fraction of HepG2 cells
Time (h) Supernatant (%) Pellet (%)
0.5 8 90
2 15 80
4 25 73
6 45 52
9 92 5
HepG2 (2.0U106) cells were incubated with loaded F-virosomes
(200 Wg F protein) in DMEM at 37‡C over a period of 9 h as de-
scribed in Fig. 4. The cells were EDTA-stripped and cell fractiona-
tion was carried out as described in Section 2. The cytosolic frac-
tions were further subjected to ultracentrifugation at 100 000Ug at
4‡C for 4 h to separate the intact PVPf -NP (£uorescence value in
the pellet) from the degraded ones (£uorescence value in the super-
natant). Fluorescence unit of the total cytosolic fraction was consid-
ered as 100%, while calculating the percent £uorescence values.
Each value is the mean of three independent determinations.
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lowed by estimating the associated £uorescence intensity (Ta-
ble 2).
3.4. Light microscopy of cytosolic delivery of PVPf -NP in
HepG2 cells
To provide direct proof in support of cytosolic localization
of PVPf -NP, we performed additional experiments (Fig. 4).
Fig. 4 shows £uorescence microscopy images for the presence
of PVPf -NP inside the HepG2 cells as a result of virosome-
mediated delivery in a time-dependent manner (panel A). The
release kinetics of FITC-Dx from PVPf -NP was compared
with the delivery of free FITC-Dx through virosomes (di¡use
pattern £uorescence, panel B). The intactness of PVPf -NP was
visualized in the form of punctate pattern of FITC £uores-
cence (arrows) until 6 h post-delivery inside the target cells.
Complete release of FITC-Dx from the NPs was observed 9 h
post-incubation of HepG2 cells with F-virosomes (cells in
panels A and B appeared same) as was con¢rmed by the
absence of any punctate pattern £uorescence. HepG2 cells
incubated with heat-treated loaded F-virosomes revealed no
detectable £uorescence. The release kinetics of FITC-Dx from
NPs appeared to be a slow and well-regulated phenomenon
amidst the complex cytosolic milieu of target cells.
4. Discussion
In recent years, encapsulation of potent cytotoxic drugs
(both hydrophilic and hydrophobic) inside polymeric hydrogel
NPs has been proven useful for reducing the toxicity and
in£uencing controlled release of such drugs at the site of ac-
tion [1,4,17]. However, targeting of such drug-loaded NPs to
various cell types both in vitro and in vivo has not yet been
precisely achieved [18]. In spite of limited success in conferring
cell/tissue speci¢city on the nanoparticulate surface [1], their
in vivo application in targeted drug delivery is severely im-
peded by the degradation of the polymer at the amide link-
ages by serum proteases [2]. To circumvent these major ob-
stacles, we have investigated the role of F-virosome in the
membrane-fusion-mediated transfer of a model drug-loaded
NP to the cytosol of HepG2 cells. The targeted nature of
this carrier is apparent from the inability of loaded F-viro-
somes in transferring PVPf -NPs to the NIH3T3 and CHO
cells (ASGP-R-de¢cient cell lines). Involvement of plasma
membrane level fusion of virosomes with HepG2 cells is con-
¢rmed from the failure of azide in inhibiting this transfer pro-
cess. Heat-treatment of F-virosomes and incubation with spe-
ci¢c antibody against F protein are known to completely
abolish the fusogenicity of F protein [5^7,13,19]. Very low
internalization of PVPf -NP by heat-treated F-virosomes
(and F-virosomes pre-incubated with anti-F antibody) with
and without the presence of azide re£ects the speci¢city of
this assay. Collectively, these observations corroborate the
role of F glycoprotein in speci¢c binding and fusion of a
genetically modi¢ed Sendai virion and a Sendai mutant (de¢-
cient in hemagglutinin^neuraminidase protein) with 1-7-1 cells
(NIH3T3 cells stably expressing ASGP-R on the cell surface)
and HepG2 cells respectively, as demonstrated earlier [19,20].
The cytosolic delivery of PVPf -NPs is further ascertained
from their subcellular distribution pattern (s 60% in the cy-
tosol) as compared to their heat-treated (ca. 21% in the cyto-
sol) counterparts. Most convincing evidence in support of
cytosolic delivery of intact PVPf -NP is revealed from the
punctate pattern of £uorescence in HepG2 cells over a di¡use
pattern of free FITC-Dx £uorescence in the presence of azide
(a potent inhibitor of endocytosis). Although the size of PVPf -
NPs is below the detection limit of the light microscope, the
presence of aggregated NPs produce images (punctate pat-
Fig. 4. Controlled release of FITC-Dx from PVPf -NP into HepG2
cells. HepG2 cells were grown on PL-coated coverslips and were in-
cubated with PVPf -NP and FITC-Dx-loaded F-virosome separately
for di¡erent times from 0.5 to 9 h and photographed (magni¢cation,
U40) as mentioned in Section 2. Panel A represents the cells deliv-
ered with PVPf -NP and panel B represents the cells delivered with
FITC-Dx through F-virosomes. C denotes the punctate nature
£uorescence of PVPf -NP inside the HepG2 cells; HC stands for
heat-treated loaded F-virosomes. This experiment was repeated four
times and was highly reproducible.
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tern) which are within the range of camera systems. This in-
ference is bolstered by our earlier observations on the inter-
action of FITC-labeled and octadecylrhodamine B-labeled
intact in£uenza virions with human RBCs [15,21]. Addition-
ally, the delivered PVPf -NP retained its integrity (punctate
pattern) in terms of holding the entrapped FITC-Dx until
6 h. This conclusion was further supported from the ultra-
centrifugation analysis of cytosolic fractions containing intact
PVPf -NP.
In essence, we have judiciously combined the power of vi-
rosomal and nanoparticulate drug delivery systems in design-
ing a novel and e⁄cient hybrid vector to transfer a model
drug inside the cytosol of liver cells in culture. As an imme-
diate consequence, the virosome-associated NPs remain pro-
tected from degradation by proteases present in the culture
media until they are delivered to the cytosol of target cells. On
the other hand, once present in the cytosol the NPs mediate
slow and controlled release of the entrapped drugs. Therefore,
we envisage a potential application of this hybrid vector in
vivo in targeting appropriate anti-cancer drugs to liver cells.
The NP-mediated slow release of drugs in cytosol is one of the
coveted goals in treating liver cancer associated with multi-
drug resistance [22]. Moreover, technology is available in our
laboratory to encapsulate several hydrophobic anti-cancer
drugs in nanoparticulate carriers [17,23] that can be in turn
delivered to the cytosol of hepatocytes through F-virosomes.
Further work is needed to extrapolate this study in delivering
drug-loaded NPs to liver cells in whole animal through such
virosomal formulations.
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